Loading
Ran the first clinical trial of CRISPR-edited T cells in humans, in patients with lung cancer.
You Lu is Professor of Thoracic Oncology at West China Hospital, Sichuan University, where he leads thoracic oncology. He ran the first clinical trial of CRISPR-edited T cells in humans, a first-in-human study of PD-1-edited T cells in patients with lung cancer, alongside research in lung cancer radiotherapy and immunotherapy. His publications include the report on the safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. His interests are lung cancer, radiation oncology, CRISPR-edited and engineered T cells, and immunotherapy.
| Title | Journal | Year |
|---|---|---|
| Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer | Nature Medicine | 2020 |
Shares West China Hospital, Sichuan University, Non-small-cell lung cancer.
Shares TCR-T cell therapy, CAR-T cell therapy.
Shares TCR-T cell therapy, CAR-T cell therapy.
Shares CRISPR functional genomics, Non-small-cell lung cancer.
Shares TCR-T cell therapy, CAR-T cell therapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/